Worldwide Clinical Trials, (“Worldwide” or the “Company”), a global contract research organization (CRO), has entered into a definitive agreement to acquire Catalyst Clinical Research, LLC (“Catalyst”), a specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. The integration of Catalyst’s two established solutions – Catalyst Oncology and Catalyst Flex – will strengthen Worldwide’s portfolio, offering customers proven expertise and new services for full-service, FSP resourcing, and hybrid solutions. Worldwide is a portfolio company of Kohlberg. Catalyst is a portfolio company of QHP Capital, L.P. (“QHP Capital”).
Read the full article: Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research //
Source: https://www.businesswire.com/news/home/20260120916893/en/Worldwide-Clinical-Trials-Enters-Definitive-Agreement-to-Acquire-Catalyst-Clinical-Research